Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-two research firms that are currently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.29.

Several research firms recently issued reports on ARVN. BTIG Research set a $16.00 target price on Arvinas and gave the stock a "buy" rating in a research report on Friday, May 2nd. UBS Group dropped their price target on Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. Wells Fargo & Company dropped their price target on Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup dropped their price target on Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research note on Monday, May 5th.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded down $0.27 during trading on Tuesday, hitting $7.50. 703,055 shares of the company's stock were exchanged, compared to its average volume of 1,494,348. Arvinas has a 52-week low of $5.90 and a 52-week high of $31.28. The business's 50-day simple moving average is $7.29 and its 200 day simple moving average is $11.23. The company has a market cap of $547.06 million, a price-to-earnings ratio of -11.33 and a beta of 2.17.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same quarter in the previous year, the company earned ($0.97) earnings per share. Arvinas's revenue for the quarter was up 646.2% on a year-over-year basis. On average, sell-side analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In other news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares in the company, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.73% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Arvinas by 18.4% during the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after purchasing an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Arvinas by 6.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after purchasing an additional 249,295 shares during the period. RTW Investments LP increased its holdings in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in Arvinas during the 4th quarter worth $42,332,000. Finally, Alyeska Investment Group L.P. purchased a new position in Arvinas during the 1st quarter worth $12,636,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.